1
|
Taborsky M, Skala T, Fedorco M, Doupal V, Sovova I, Jarkovsky J, Benesova K, Bezdekova M, Vicha M, Danek J, Kautzner J. Effectiveness of ICD therapy in real clinical practice. The Olomouc ICD Registry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2023; 167:225-235. [PMID: 34916673 DOI: 10.5507/bp.2021.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Accepted: 12/08/2021] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Clinical parameters linked to a low benefit of ICD implantation and increased mortality risks are needed for an individualized assessment of potential benefits and risks of ICD implantation. METHODS Analysis of a prospective registry of all patients hospitalized from 2009 to 2019 in a single centre for a first implantation of any type of ICD. RESULTS A total of 2,681 patients were included in the registry. Until the end of follow-up (38.4 ± 29.1 months), 682 (25.4%) patients died. The one-year mortality in all patients, the one-year CV mortality, the three-year mortality in all patients, and the three-year CV mortality were 7.8%, 5.7%, 20.6%, and 14.8%, respectively. There was a statistically significant difference when the subgroups were compared according to the type of cardiomyopathy. No significant difference was found between primary and secondary prevention and between the types of devices. Male gender, age ≥ 75 years, diabetes mellitus, and atrial fibrillation were associated with a significantly increased mortality risk. CONCLUSION In an analysis of a long-term follow-up of 2,681 ICD patients, we found no mortality difference between patients with ischemic or non-ischemic cardiomyopathy and in the device type. A higher mortality risk was found in men, patients older than 75 years, diabetics, and those with atrial fibrillation.
Collapse
Affiliation(s)
- Milos Taborsky
- Department of Internal Medicine I - Cardiology, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic
| | - Tomas Skala
- Department of Internal Medicine I - Cardiology, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic
| | - Marian Fedorco
- Department of Internal Medicine I - Cardiology, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic
| | - Vlastimil Doupal
- Department of Internal Medicine I - Cardiology, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic
| | - Ingrid Sovova
- Department of Internal Medicine I - Cardiology, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic
| | - Jiri Jarkovsky
- Institute of Health Information and Statistics of the Czech Republic, Palackeho nam. 4, P.O. BOX 60, 128 01 Praha 2, Czech Republic
- Institute of Biostatistics and Analyses at the Faculty of Medicine of the Masaryk University (IBA FM MU) in Brno, Czech Republic
| | - Klara Benesova
- Institute of Health Information and Statistics of the Czech Republic, Palackeho nam. 4, P.O. BOX 60, 128 01 Praha 2, Czech Republic
- Institute of Biostatistics and Analyses at the Faculty of Medicine of the Masaryk University (IBA FM MU) in Brno, Czech Republic
| | - Monika Bezdekova
- Institute of Health Information and Statistics of the Czech Republic, Palackeho nam. 4, P.O. BOX 60, 128 01 Praha 2, Czech Republic
| | - Marek Vicha
- Department of Internal Medicine I - Cardiology, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic
| | - Josef Danek
- Department of Cardiology, Central Military Hospital Prague, U Vojenske nemocnice 1200, 169 02 Praha 6, Czech Republic
| | - Josef Kautzner
- Institute for Clinical and Experimental Medicine, Videnska 1958, 140 21 Praha 4, Czech Republic
| |
Collapse
|
2
|
Jarkovsky J, Benesova K, Cerny V, Razova J, Kala P, Dolina J, Majek O, Sebestova S, Bezdekova M, Melicharova H, Snajdrova L, Dusek L, Parenica J. Covidogram as a simple tool for predicting severe course of COVID-19: population-based study. BMJ Open 2021; 11:e045442. [PMID: 33622955 PMCID: PMC7907625 DOI: 10.1136/bmjopen-2020-045442] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
OBJECTIVES COVID-19 might either be entirely asymptomatic or manifest itself with a large variability of disease severity. It is beneficial to identify early patients with a high risk of severe course. The aim of the analysis was to develop a prognostic model for the prediction of the severe course of acute respiratory infection. DESIGN A population-based study. SETTING Czech Republic. PARTICIPANTS The first 7455 consecutive patients with COVID-19 who were identified by reverse transcription-PCR testing from 1 March 2020 to 17 May 2020. PRIMARY OUTCOME Severe course of COVID-19. RESULT Of a total 6.2% of patients developed a severe course of COVID-19. Age, male sex, chronic kidney disease, chronic obstructive pulmonary disease, recent history of cancer, chronic heart failure, acid-related disorders treated with proton-pump inhibitors and diabetes mellitus were found to be independent negative prognostic factors (Area under the ROC Curve (AUC) was 0.893). The results were visualised by risk heat maps, and we called this diagram a 'covidogram'. Acid-related disorders treated with proton-pump inhibitors might represent a negative prognostic factor. CONCLUSION We developed a very simple prediction model called 'covidogram', which is based on elementary independent variables (age, male sex and the presence of several chronic diseases) and represents a tool that makes it possible to identify-with a high reliability-patients who are at risk of a severe course of COVID-19. Obtained results open clinically relevant question about the role of acid-related disorders treated by proton-pump inhibitors as predictor for severe course of COVID-19.
Collapse
Affiliation(s)
- Jiri Jarkovsky
- Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Institute of Health Information and Statistics of the Czech Republic, Praha, Czech Republic
| | - Klara Benesova
- Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Institute of Health Information and Statistics of the Czech Republic, Praha, Czech Republic
| | - Vladimir Cerny
- Department of Anaesthesiology, Perioperative Medicine and Intensive Care, J.E. Purkinje University and Masaryk Hospital, Usti nad Labem, Czech Republic
- Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Jarmila Razova
- Ministry of Health of the Czech Republic, Praha, Czech Republic
| | - Petr Kala
- Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Internal and Cardiology Department, University Hospital Brno, Brno, Czech Republic
| | - Jiri Dolina
- Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Gastroenterology and Internal Department, University Hospital Brno, Brno, Czech Republic
| | - Ondrej Majek
- Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Institute of Health Information and Statistics of the Czech Republic, Praha, Czech Republic
| | - Silvie Sebestova
- Institute of Health Information and Statistics of the Czech Republic, Praha, Czech Republic
| | - Monika Bezdekova
- Institute of Health Information and Statistics of the Czech Republic, Praha, Czech Republic
| | - Hana Melicharova
- Institute of Health Information and Statistics of the Czech Republic, Praha, Czech Republic
| | - Lenka Snajdrova
- Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Institute of Health Information and Statistics of the Czech Republic, Praha, Czech Republic
| | - Ladislav Dusek
- Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Institute of Health Information and Statistics of the Czech Republic, Praha, Czech Republic
| | - Jiri Parenica
- Institute of Health Information and Statistics of the Czech Republic, Praha, Czech Republic
- Faculty of Medicine, Masaryk University, Brno, Czech Republic
- Internal and Cardiology Department, University Hospital Brno, Brno, Czech Republic
| |
Collapse
|
3
|
Brychtova S, Bezdekova M, Brychta T, Tichy M. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 2008; 55:273-279. [PMID: 18505336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Vascular endothelial growth factors (VEGFs) have a leading role among variety of angiogenic factors. Together with their receptors, they play an important role in endothelial cell proliferation and/or elongation, migration and vascular morphogenesis. In order to determine their possible role in malignant melanoma progression, VEGF (representing VEGFA), VEGF-C and VEGFR-1, -2, -3 immunohistochemical expression on formalin-fixed, paraffin-embedded tissue sections were evaluated. A total of 196 tissue samples consisting of 130 malignant melanomas (MM) with various vertical depth of invasion, 15 metastatic melanomas, and 66 nevi including dysplastic nevi and melanocytic nevi were analysed. Production of both VEGFs were common in benign melanocytic tumors while MM exhibited significant upregulation of VEGF (p<0.0027) and VEGF-C (p<0.0001). The proteins were also detected within stromal cells surrounding tumors, particularly in fibrocytes/ fibroblasts, macrophages and endothelial cells. They also exhibited significant increase in malignant lesions (p<0.0001). VEGFRs were localized in tumor, as well in stromal cells. Although expression of VEGF receptors was significantly higher in MM versus nevi (p<0.002 for VEGFR-1, p<0.004 for VEGFR-2 and p<0.0001 for VEGFR-3), a considerable percentage of MM were negative. There were no correlations between sentinel node positivity and all investigated proteins. When clinical outcome was evaluated, progression of the disease positively correlated with VEGF (p<0,007) and VEGF-C (p<0,008) expression VEGF (p<0.001) and VEGF-C (p<0.0001) positively correlated with nestin expression in the capillary endothelium, which was used for angiogenesis detection. Our work demonstrated that upregulation of VEGFs is associated with progression of malignant melanomas. The protein expression in the tumor microenvironment highlights their importance in malignant stromal phenotype which may serve as a potential target for the anticancer therapy.
Collapse
Affiliation(s)
- S Brychtova
- Laboratory of Molecular Pathology and Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
| | | | | | | |
Collapse
|